Sort
261,768 grants matching “gene therapy”
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
$12,618,678Bradley F Boeve · Mayo Clinic Rochester · U19 · FY2023 · AG
Evaluating New Nicotine Standards for Cigarettes
$12,546,088Eric Christian Donny · University Of Pittsburgh At Pittsburgh · U54 · FY2015 · DA
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
$12,500,000Susan Abushakra · Alzheon, Inc. · R01 · FY2021 · AG
The Center for Therapeutic Targeting of EWS-oncoproteins
$12,500,000Kimberly Stegmaier · Dana-Farber Cancer Inst · U54 · FY2018 · CA
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
$12,228,673Bradley F Boeve · Mayo Clinic Rochester · U19 · FY2020 · AG
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers
$12,197,183John M Maris · Children'S Hosp Of Philadelphia · U54 · FY2018 · CA
Final clinical studies for submission of a pre-market approval application to the FDA for a Bionic Pancreas that automates type 1 diabetes management
$11,957,319Edward Damiano · Boston University (Charles River Campus) · UC4 · FY2016 · DK
A once-weekly oral methadone for maintenance therapy for opioid use disorder
$11,699,793Richard Scranton · Lyndra Therapeutics, Inc. · UH3 · FY2021 · DA
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
$11,665,635James Dale Berry · Massachusetts General Hospital · U01 · FY2024 · NS
Novel Dopamine D3/D2 Receptor Ligands
$11,662,952Amy Hauck Newman · National Institute On Drug Abuse · ZIA · FY2023 · DA
DCTD Biopharmaceutical Development
$11,541,306Larry Arthur · Science Applications International Corp · N01 · FY2009 · CA
Targeting SS18-SSX biology in synovial sarcomagenesis
$11,520,799Kevin Bruce Jones · University Of Utah · U54 · FY2018 · CA
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
$11,203,040James Dale Berry · Massachusetts General Hospital · U01 · FY2023 · NS
Cardiovascular Inflammation Reduction Trial (CIRT)
$11,048,538Paul M. Ridker · Brigham And Women'S Hospital · U01 · FY2016 · HL
Consortia for Innovative AIDS Research in Nonhuman Primates
$11,020,286Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2017 · AI
California National Primate Research Center
$11,016,202Cameron S. Carter · University Of California At Davis · P51 · FY2016 · OD
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
$11,000,000Susan Abushakra · Alzheon, Inc. · R01 · FY2022 · AG
CRTP CCR Dedicated Cores
$10,969,625Mariam Malik · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA
REGIONAL PRIMATE RESEARCH CENTER
$10,950,971Oregon Health And Science University · P51 · FY2003 · RR
Clinical Core
$10,927,979Ziad Nahas · University Of Minnesota · U54 · FY2024 · AT
California National Primate Research Center
$10,839,393Harris A Lewin · University Of California At Davis · P51 · FY2015 · OD
A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases
$10,834,632Yong-Hui Jiang · Yale University · UG3 · FY2024 · TR
Understanding and Overcoming Resistance to Immunotherapies in Childhood Cancers
$10,785,733Crystal Mackall · Children'S Hosp Of Philadelphia · U54 · FY2018 · CA
The Role Of Subclinical Infection And Cytokines In Preterm Parturition
$10,681,181Roberto Romero · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2023 · HD
A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases
$10,672,633Yong-Hui Jiang · Yale University · UG3 · FY2025 · TR